Which has better earnings and valuation, PFE or AMGN?

Pfizer has higher revenue and earnings than Amgen. Pfizer is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $63.31B 2.27 $7.77B $1.31 19.28 Amgen $36.75B 4.96 $7.71B $14.37 23.49

Is PFE or AMGN more profitable?

Amgen has a net margin of 20.96% compared to Pfizer's net margin of 11.83%. Amgen's return on equity of 137.41% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 11.83% 19.44% 8.41% Amgen 20.96% 137.41% 13.28%

Does the media prefer PFE or AMGN?

In the previous week, Pfizer had 39 more articles in the media than Amgen. MarketBeat recorded 90 mentions for Pfizer and 51 mentions for Amgen. Amgen's average media sentiment score of 1.27 beat Pfizer's score of 1.11 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 63 Very Positive mention(s) 12 Positive mention(s) 6 Neutral mention(s) 6 Negative mention(s) 3 Very Negative mention(s) Positive Amgen 39 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Is PFE or GILD more profitable?

Gilead Sciences has a net margin of 30.99% compared to Pfizer's net margin of 11.83%. Gilead Sciences' return on equity of 48.19% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 11.83% 19.44% 8.41% Gilead Sciences 30.99% 48.19% 18.28%

Does the media favor PFE or GILD?

In the previous week, Pfizer had 6 more articles in the media than Gilead Sciences. MarketBeat recorded 90 mentions for Pfizer and 84 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.30 beat Pfizer's score of 1.11 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 63 Very Positive mention(s) 12 Positive mention(s) 6 Neutral mention(s) 6 Negative mention(s) 3 Very Negative mention(s) Positive Gilead Sciences 70 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, PFE or MRNA?

Pfizer has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $63.31B 2.27 $7.77B $1.31 19.28 Moderna $1.94B 13.05 -$2.82B -$8.15 N/A

Is PFE or MRNA more profitable?

Pfizer has a net margin of 11.83% compared to Moderna's net margin of -143.55%. Pfizer's return on equity of 19.44% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 11.83% 19.44% 8.41% Moderna -143.55% -26.64% -19.32%

Does the media prefer PFE or MRNA?

In the previous week, Pfizer had 48 more articles in the media than Moderna. MarketBeat recorded 90 mentions for Pfizer and 42 mentions for Moderna. Pfizer's average media sentiment score of 1.11 beat Moderna's score of 0.59 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 63 Very Positive mention(s) 12 Positive mention(s) 6 Neutral mention(s) 6 Negative mention(s) 3 Very Negative mention(s) Positive Moderna 21 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 9 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, PFE or NVAX?

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $63.31B 2.27 $7.77B $1.31 19.28 Novavax $596.34M 2.52 $440.30M -$0.58 N/A

Is PFE or NVAX more profitable?

Pfizer has a net margin of 11.83% compared to Novavax's net margin of -14.73%. Pfizer's return on equity of 19.44% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 11.83% 19.44% 8.41% Novavax -14.73% -14.82% 1.23%

Does the media prefer PFE or NVAX?

In the previous week, Pfizer had 84 more articles in the media than Novavax. MarketBeat recorded 90 mentions for Pfizer and 6 mentions for Novavax. Pfizer's average media sentiment score of 1.11 beat Novavax's score of 0.32 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 63 Very Positive mention(s) 12 Positive mention(s) 6 Neutral mention(s) 6 Negative mention(s) 3 Very Negative mention(s) Positive Novavax 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, PFE or ABBV?

Pfizer has higher revenue and earnings than AbbVie. Pfizer is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $63.31B 2.27 $7.77B $1.31 19.28 AbbVie $61.16B 6.26 $4.23B $2.03 106.71

Is PFE or ABBV more profitable?

Pfizer has a net margin of 11.83% compared to AbbVie's net margin of 5.79%. Pfizer's return on equity of 19.44% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 11.83% 19.44% 8.41% AbbVie 5.79% -576.45% 13.39%

Does the media refer more to PFE or ABBV?

In the previous week, Pfizer had 24 more articles in the media than AbbVie. MarketBeat recorded 90 mentions for Pfizer and 66 mentions for AbbVie. Pfizer's average media sentiment score of 1.11 beat AbbVie's score of 1.06 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 63 Very Positive mention(s) 12 Positive mention(s) 6 Neutral mention(s) 6 Negative mention(s) 3 Very Negative mention(s) Positive AbbVie 45 Very Positive mention(s) 8 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Pfizer (PFE) Competitors

$25.26 -0.67 (-2.57%)

Closing price 03:59 PM Eastern

Extended Trading

$25.26 +0.00 (+0.01%)

As of 06:10 PM Eastern

Compare

PFE vs. AMGN, GILD, MRNA, NVAX, and ABBV

Should you buy Pfizer stock or one of its competitors? MarketBeat compares Pfizer with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pfizer include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Novavax (NVAX), and AbbVie (ABBV). These companies are all part of the "medical" sector.

How does Pfizer compare to Amgen?

Pfizer (NYSE:PFE) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Pfizer has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Amgen has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

Amgen has a net margin of 20.96% compared to Pfizer's net margin of 11.83%. Amgen's return on equity of 137.41% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Amgen	20.96%	137.41%	13.28%

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.8%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.0%. Pfizer pays out 131.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 70.1% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years and Amgen has increased its dividend for 14 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Pfizer presently has a consensus target price of $28.82, suggesting a potential upside of 14.13%. Amgen has a consensus target price of $354.42, suggesting a potential upside of 4.98%. Given Pfizer's higher possible upside, equities analysts clearly believe Pfizer is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.25
Amgen	2 Sell rating(s)	15 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.45

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.6% of Pfizer shares are owned by insiders. Comparatively, 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Pfizer had 39 more articles in the media than Amgen. MarketBeat recorded 90 mentions for Pfizer and 51 mentions for Amgen. Amgen's average media sentiment score of 1.27 beat Pfizer's score of 1.11 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	63 Very Positive mention(s)	12 Positive mention(s)	6 Neutral mention(s)	6 Negative mention(s)	3 Very Negative mention(s)	Positive
Amgen	39 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Pfizer has higher revenue and earnings than Amgen. Pfizer is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$63.31B	2.27	$7.77B	$1.31	19.28
Amgen	$36.75B	4.96	$7.71B	$14.37	23.49

Summary

Amgen beats Pfizer on 14 of the 20 factors compared between the two stocks.

How does Pfizer compare to Gilead Sciences?

Pfizer (NYSE:PFE) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Gilead Sciences has a net margin of 30.99% compared to Pfizer's net margin of 11.83%. Gilead Sciences' return on equity of 48.19% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Gilead Sciences	30.99%	48.19%	18.28%

Gilead Sciences has lower revenue, but higher earnings than Pfizer. Gilead Sciences is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$63.31B	2.27	$7.77B	$1.31	19.28
Gilead Sciences	$29.44B	5.22	$8.51B	$7.34	16.86

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.8%. Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.7%. Pfizer pays out 131.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out 44.7% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

68.4% of Pfizer shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 0.6% of Pfizer shares are held by company insiders. Comparatively, 0.3% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pfizer has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

In the previous week, Pfizer had 6 more articles in the media than Gilead Sciences. MarketBeat recorded 90 mentions for Pfizer and 84 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.30 beat Pfizer's score of 1.11 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	63 Very Positive mention(s)	12 Positive mention(s)	6 Neutral mention(s)	6 Negative mention(s)	3 Very Negative mention(s)	Positive
Gilead Sciences	70 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pfizer presently has a consensus target price of $28.82, suggesting a potential upside of 14.13%. Gilead Sciences has a consensus target price of $158.41, suggesting a potential upside of 28.00%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Gilead Sciences is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.25
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	25 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Gilead Sciences beats Pfizer on 12 of the 20 factors compared between the two stocks.

How does Pfizer compare to Moderna?

Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Pfizer has a net margin of 11.83% compared to Moderna's net margin of -143.55%. Pfizer's return on equity of 19.44% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Moderna	-143.55%	-26.64%	-19.32%

Pfizer has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$63.31B	2.27	$7.77B	$1.31	19.28
Moderna	$1.94B	13.05	-$2.82B	-$8.15	N/A

68.4% of Pfizer shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 0.6% of Pfizer shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pfizer has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

In the previous week, Pfizer had 48 more articles in the media than Moderna. MarketBeat recorded 90 mentions for Pfizer and 42 mentions for Moderna. Pfizer's average media sentiment score of 1.11 beat Moderna's score of 0.59 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	63 Very Positive mention(s)	12 Positive mention(s)	6 Neutral mention(s)	6 Negative mention(s)	3 Very Negative mention(s)	Positive
Moderna	21 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	9 Negative mention(s)	0 Very Negative mention(s)	Positive

Pfizer currently has a consensus price target of $28.82, indicating a potential upside of 14.13%. Moderna has a consensus price target of $36.60, indicating a potential downside of 42.78%. Given Pfizer's stronger consensus rating and higher possible upside, analysts plainly believe Pfizer is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.25
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Summary

Pfizer beats Moderna on 13 of the 17 factors compared between the two stocks.

How does Pfizer compare to Novavax?

Pfizer (NYSE:PFE) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

In the previous week, Pfizer had 84 more articles in the media than Novavax. MarketBeat recorded 90 mentions for Pfizer and 6 mentions for Novavax. Pfizer's average media sentiment score of 1.11 beat Novavax's score of 0.32 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	63 Very Positive mention(s)	12 Positive mention(s)	6 Neutral mention(s)	6 Negative mention(s)	3 Very Negative mention(s)	Positive
Novavax	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 0.6% of Pfizer shares are owned by company insiders. Comparatively, 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pfizer presently has a consensus target price of $28.82, suggesting a potential upside of 14.13%. Novavax has a consensus target price of $13.00, suggesting a potential upside of 42.39%. Given Novavax's higher possible upside, analysts clearly believe Novavax is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.25
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22

Pfizer has a net margin of 11.83% compared to Novavax's net margin of -14.73%. Pfizer's return on equity of 19.44% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Novavax	-14.73%	-14.82%	1.23%

Pfizer has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Novavax has a beta of 2.45, meaning that its share price is 145% more volatile than the broader market.

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$63.31B	2.27	$7.77B	$1.31	19.28
Novavax	$596.34M	2.52	$440.30M	-$0.58	N/A

Summary

Pfizer beats Novavax on 12 of the 16 factors compared between the two stocks.

How does Pfizer compare to AbbVie?

Pfizer (NYSE:PFE) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Pfizer has higher revenue and earnings than AbbVie. Pfizer is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$63.31B	2.27	$7.77B	$1.31	19.28
AbbVie	$61.16B	6.26	$4.23B	$2.03	106.71

Pfizer has a net margin of 11.83% compared to AbbVie's net margin of 5.79%. Pfizer's return on equity of 19.44% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
AbbVie	5.79%	-576.45%	13.39%

68.4% of Pfizer shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 0.6% of Pfizer shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.8%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.2%. Pfizer pays out 131.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Pfizer has increased its dividend for 16 consecutive years and AbbVie has increased its dividend for 53 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.

Pfizer currently has a consensus target price of $28.82, suggesting a potential upside of 14.13%. AbbVie has a consensus target price of $253.43, suggesting a potential upside of 16.99%. Given AbbVie's stronger consensus rating and higher probable upside, analysts plainly believe AbbVie is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.25
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88

In the previous week, Pfizer had 24 more articles in the media than AbbVie. MarketBeat recorded 90 mentions for Pfizer and 66 mentions for AbbVie. Pfizer's average media sentiment score of 1.11 beat AbbVie's score of 1.06 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	63 Very Positive mention(s)	12 Positive mention(s)	6 Neutral mention(s)	6 Negative mention(s)	3 Very Negative mention(s)	Positive
AbbVie	45 Very Positive mention(s)	8 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Pfizer has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Summary

Pfizer and AbbVie tied by winning 10 of the 20 factors compared between the two stocks.

Get Pfizer News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PFE vs. The Competition

Export

Metric	Pfizer	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$143.94B	$302.67B	$6.40B	$23.18B
Dividend Yield	6.62%	2.78%	2.67%	4.07%
P/E Ratio	19.28	27.04	24.51	31.62
Price / Sales	2.27	4.84	553.73	103.64
Price / Cash	5.92	13.18	43.94	24.31
Price / Book	1.65	7.72	10.70	4.68
Net Income	$7.77B	$11.61B	$3.57B	$1.08B
7 Day Performance	-3.50%	-3.09%	0.56%	-0.26%
1 Month Performance	-0.20%	0.48%	3.57%	2.18%
1 Year Performance	5.78%	18.05%	28.49%	24.66%

Pfizer Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PFE Pfizer	4.0879 of 5 stars	$25.26 -2.6%	$28.82 +14.1%	+8.1%	$143.94B	$63.31B	19.28	75,000	Trending News High Trading Volume
AMGN Amgen	4.3719 of 5 stars	$345.66 -1.1%	$353.81 +2.4%	+17.8%	$188.67B	$36.75B	24.05	31,500	Positive News Analyst Forecast
GILD Gilead Sciences	4.9188 of 5 stars	$128.10 -0.8%	$156.93 +22.5%	+16.2%	$160.36B	$29.44B	17.45	17,000	Positive News Ex-Dividend Analyst Forecast Insider Trade
MRNA Moderna	1.2407 of 5 stars	$47.60 +0.3%	$36.60 -23.1%	+141.9%	$18.82B	$1.94B	N/A	4,700	Trending News Analyst Forecast Insider Trade Options Volume Gap Up
NVAX Novavax	1.8132 of 5 stars	$8.62 -9.2%	$12.13 +40.7%	+46.4%	$1.56B	$1.12B	N/A	1,990

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PFE) was last updated on 6/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pfizer (PFE) Competitors